NHD Global
Cosmetic & Skin · Source-reviewed dossier
Source-Reviewed Research Dossier
Melanotan II is a man-made peptide used only in research. It is studied because it switches on several melanocortin receptors, a family of cell switches involved in skin pigment, appetite, sexual arousal and some automatic body functions. People have used unregulated versions hoping for darker skin or sexual effects. Published human reports instead describe serious harm, including body-wide toxicity with muscle breakdown and a long painful erection after an overdose. These reports cannot tell us how often such events happen. Melanotan II is not an approved medicine, and products sold online may not match their labels. Research material identity is documented separately from any finding.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A published case described systemic toxicity with rhabdomyolysis after Melanotan II use.
A case report cannot estimate incidence but identifies a credible serious-harm signal.
Read the primary studyA clinical report documented prolonged priapism and systemic effects after Melanotan II overdose.
Unregulated product composition and dose add uncertainty rather than reassurance.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
A case report cannot estimate incidence but identifies a credible serious-harm signal.
View primary recordUnregulated product composition and dose add uncertainty rather than reassurance.
View primary recordThird-party publications selected for direct relevance.
Case report. 2012. PMID 23121206.
Case report. 2013. PMID 23537392.
Concise answers for researchers comparing identity, evidence and catalog variants.
It is studied as a research peptide that activates several melanocortin receptors, a system linked to pigment, appetite and sexual response. Published human reports describe harm, not benefit. One case documented body-wide toxicity with muscle breakdown and kidney stress. Another described prolonged priapism and sympathomimetic symptoms after an overdose. These are individual reports, so they flag a serious safety signal but cannot show how common such events are or at what dose.
The same receptors that influence arousal and pigment also sit in pathways controlling blood pressure, heart rate, sweating and muscle chemistry. A strong, broad signal could therefore cause fast heart rate, agitation and, in the published overdose case, muscle breakdown with kidney stress. These are human case reports. They point to a possible mechanism and a serious harm signal. They do not measure how often reactions occur or at what exposure.
The human literature includes small experiments and case reports, with no approved product and meaningful safety uncertainty.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Melanotan II has limited early human exposure data and documented harms from unregulated use. A three-person tanning pilot cannot outweigh later toxicity reports or…
Updated October 1, 2026
Melanotan II is a cyclic heptapeptide analogue of α-MSH. Its lactam ring, D-phenylalanine and terminal modifications are identity-defining.
Updated October 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: MT2 · 10 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
